Vistasp Sethna

Dr. Vistasp Sethna


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2025 in Vaccine
Verified
Journal Article
Open access
VSVistasp Sethna
Vistasp Sethna
AAA. Apte
A. Apte
SSS. Sanghavi
S. Sanghavi
YTY. Tang
Y. Tang
CPC. Poonawalla
C. Poonawalla
ABA. Bavdekar
A. Bavdekar
Reduction in the vaccine serotype (VT) carriage is a surrogate marker of pneumococcal vaccines protection. PNEUMOSIL®, a 10-valent pneumococcal conjugate vaccine (PCV) has been recently introduced in the national immunization program of India in a 2 + 1 schedule. Owing to scarcity of data about impact of PNEUMOSIL® vaccination on VT-carriage, the current study was conducted in Indian children to assess its impact. This was a community-based cross-sectional observational study conducted between November 2022-March 2023 in rural areas of Pune, India. The study population included healthy children either fully vaccinated with PNEUMOSIL® 2 + 1 schedule through Universal Immunization Program or PCV-naïve. The vaccinated group was enrolled at least 4 months after receipt of the last PCV dose. Nasopharyngeal swabs were collected upon enrolment using World Health Organization methods in all children to isolate Streptococcus pneumoniae and identify serotypes using a Quellung test. The VT-carriage were compared between PCV-vaccinated and PCV-naïve using univariate and multivariate logistic regression. The study enrolled 700 healthy children; 350 children aged 15-20 months previously fully vaccinated with PNEUMOSIL® 2 + 1 schedule through UIP and 350 PCV-naïve children aged 16-21 months. Overall S. pneumoniae carriage in PCV-vaccinated and PCV-naïve groups was 63·1 % (95 % CI 57·9 %-68·2 %) and 66·3 % (95 % CI 61·1 %-71·2 %), respectively (p = 0·384). VT-carriage occurred in 23·4 % (95 % CI 19·1 %-28·2 %) of vaccinated children and 30·9 % (95 % CI 26·1 %-36·0 %) of PCV-naïve participants (24·3 % reduction, p = 0·027). After adjusting for colonization risk factors, PNEUMOSIL® vaccination was associated with 32 % reduction in odds of VT colonization compared with PCV-naïve participants [OR = 0·68; 95 % CI 0·49-0·96]. The observed reduction in VT-carriage amongst Indian children was comparable to that observed with other PCVs that have demonstrated marked declines in disease transmission. These results suggest PNEUMOSIL® could be an effective public health tool in decreasing pneumococcal disease.

10 April 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
Tung Son VuTung Son Vu
Tung Son Vu
BABui Dang The Anh
Bui Dang The Anh
VHVu Ngoc Hoan
Vu Ngoc Hoan
THThan Van Hoang
Than Van Hoang
LBLinh Kim Bui Bui
Linh Kim Bui Bui
PHPham Van Hung
Pham Van Hung
Background: Pneumococcal conjugate vaccines (PCVs) prevent severe disease in children, but high costs limit access. PCV10-SII (PNEUMOSIL), a 10-valent PCV prequalified by the World Health Organization (WHO) in 2019, offers a cost-effective alternative. This study assessed its safety and immunogenicity in Vietnamese children aged 6 weeks–24 months. Methods: An open-label, single-arm study enrolled 304 children in three age groups: 6 weeks–6 months (n = 151), >6–12 months (n = 76), and >12–24 months (n = 77). Participants received two or three doses. Safety was evaluated through immediate reactions, adverse events (AEs), serious adverse events (SAEs), and withdrawals. Immunogenicity was measured 28 days after the final dose using serotype-specific IgG geometric mean concentrations (GMCs), opsonophagocytic activity (OPA) titers, and seroresponse rates. The trial was approved by the IRB of the National Ethics Council (code: No. 75/CN-HĐĐĐ on date 4 June 2021) and was registered with ClinicalTrials.gov, NCT05140720. Results: Of 304 enrolled participants, 294 (96.7%) completed follow-up. No immediate adverse events or serious adverse events occurred. Unsolicited adverse events were reported in 17%, mainly respiratory, while serious adverse events occurred in 4%. Mild local/systemic reactions (e.g., injection site pain, crying) resolved without sequelae. Immunogenicity was strong, with GMCs 1.8–9.11 µg/mL, GMTs 277.8–22,342, and seroresponse rates >90% for 9 of 10 serotypes, serotype 6B demonstrated a slightly lower seroresponse rate of 88.6%. Conclusions: PCV10-SII demonstrated favorable safety and robust immunogenicity, supporting its inclusion in national immunization programs as an affordable option for pneumococcal disease prevention.